The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Open accessAbstract
Background & aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver disease that can lead to cirrhosis. While liver biopsy is considered the reference standard for the histologic diagnosis of NASH and staging of fibrosis, its use in clinical practice is limited. Non-invasive tests (NITs) are increasingly being used to identify and stage liver fibrosis in patients with NASH, and several can assess liver-related outcomes. We report changes in various NITs in patients treated with obeticholic acid (OCA) or placebo in the phase III REGENERATE study.Methods Patients with NASH and fibrosis stage F2 or F3 (n = 931) were randomized (1:1:1) to receive placebo, OCA 10 mg, or OCA 25 mg once daily. Various NITs based on clinical chemistry and/or imaging were evaluated at baseline and throughout the study.Results Rapid, sustained reductions from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase levels, as well as in Fibrosis-4 (FIB-4), FibroTest, FibroMeter, and FibroScan-AST scores were observed in OCA-treated vs. placebo-treated patients. Reduction in liver stiffness by vibration-controlled transient elastography was observed in the OCA 25 mg group vs. the placebo group at Month 18. NIT changes were associated with shifts in histologic fibrosis stage. The greatest improvements were observed in patients with ≥1-stage fibrosis improvement; however, improvements in ALT, AST, FIB-4, and FibroTest were also observed in OCA-treated patients whose histologic fibrosis remained stable.Conclusions Based on the REGENERATE Month 18 interim analysis, rapid and sustained improvements in various NITs were observed with OCA treatment. Dynamic changes in selected NITs separated histologic responders from non-responders. These results suggest that NITs may be useful in assessing histologic response to OCA therapy. CLINICALTRIALS.Gov number NCT02548351 LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is a chronic, progressive liver disease that can lead to cirrhosis. To diagnose and assess liver fibrosis (scarring) in patients with NASH, non-invasive tests (NITs) are increasingly being used rather than liver biopsy, which is invasive, expensive, and can be risky. In the REGENERATE study, which is evaluating the effects of obeticholic acid vs. placebo in patients with NASH, various NITs were also evaluated. This analysis shows that improvements in levels of certain blood components, as well as favorable results of ultrasound imaging and proprietary tests of liver function, were associated with improvements in liver fibrosis after treatment with obeticholic acid, suggesting that NITs may be useful alternatives to liver biopsy in assessing NASH patients' response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some improvements in NITs were related to the treatment arm but not per se to histological response, whereas others, e.g. VCTE or ELF, correlated better with changes in fi brosis stage regardless of the treatment arm, suggesting that they re fl ect histological changes regardless of a drug ' s mode of action.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some improvements in NITs were related to the treatment arm but not per se to histological response, whereas others, e.g. VCTE or ELF, correlated better with changes in fi brosis stage regardless of the treatment arm, suggesting that they re fl ect histological changes regardless of a drug ' s mode of action.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The most extensive analysis in that regard is from the REGENERATE trial of obeticholic acid, 267 which analysed NIT responses between histological responders and nonresponders.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
Sandrin, L., Fourquet, B., Hasquenoph, J.-M., Yon, S., Fournier, C., Mal, F., Christidis, C., Ziol, M., Poulet, B., Kazemi, F., et al. (2003) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2003.07.001 · Cited by 2,734
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationComparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A. D., Murray, K. F., Tetri, B., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,561
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citation
Cited by
Sorted by citations
Items 101–164 of 164
Gut microbiome in non-alcoholic fatty liver disease
Mpountouridis, A., Tsigalou, C., Bezirtzoglou, I., Bezirtzoglou, E., & Stavropoulou, E. (2025) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2024.1534431 · Cited by 12
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review
Tun, K. M., Noureddin, N., & Noureddin, M. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000066 · Cited by 8
Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
Girisa, S., Aswani, B. S., Manickasamy, M. K., Hegde, M., Alqahtani, M. S., Abbas, M., Sethi, G., & Kunnumakkara, A. B. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2487465 · Cited by 8
Loomba, R. S., Daniel, P. C., Wang, Y., Bettencourt, R., Madamba, E. V., Siddiqi, H., Richards, L., Gottwald, M. D., Feng, S., Margalit, M., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.039 · Cited by 7
Transcriptional Control of Trpm6 by the Nuclear Receptor FXR
Kim, E. Y., & Lee, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041980 · Cited by 7
Wu, D., Liu, J., Guo, Z., Wang, L., Yao, Z., Wu, Q., Lu, Y., & Lv, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114708 · Cited by 6
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 7
Lv, X.-L., Li, W., Sun, F., An, Y.-Z., Sun, N., Lv, X.-P., & Gao, X. (2024) · BioMetals · doi:10.1007/s10534-024-00588-z · Cited by 6
Research Progress of Natural Products with the Activity of Anti-nonalcoholic Steatohepatitis
Wang, R., Mao, Y., Yu, C., Rong, Z., Wang, R., Wang, Y., Lv, L., Gao, Y., Wang, Z., & Zhang, H. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575306598240503054317 · Cited by 6
Kamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Sasikanth, T., Ahammed, A., Rahman, S. I., Wickramarachchi, A. W., Parajuli, N., Khatiwada, S., & Dutta, D. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.8 · Cited by 6
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 10
Ho, H.-T., Shih, Y., Huang, T., Fang, W., Liu, C.-H., Lin, J., Hsiang, C., Chu, K., Hsiong, C.-H., Chen, G.-J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05686-7 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 5
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review
Demidova, T. Y., & Омариевна, У. Ф. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202435 · Cited by 4
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
Wang, Y., Yang, L., Xu, Q., Liu, T., He, H., Liu, L., & Yin, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010032 · Cited by 5
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Chen, C., Zhou, X., Cheng, W., Li, X., Zhang, B., Tu, J., Meng, J., Peng, Y., Duan, X., Yu, Q.-M., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107940 · Cited by 3
Bollinger, B., Cotter, R. J., Deng, Y., Ilagan‐Ying, Y. C., & Gupta, V. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08724-y · Cited by 3
Novel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
Amato, F., Marano, M., Gjini, K., VAIRA, L., Bugianesi, E., & Armandi, A. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03186-9 · Cited by 4
Dinerman, S., & Shu, Y. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5010007 · Cited by 4
Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment
Arredouani, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106445 · Cited by 3
The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
Wang, X., Ning, C., Cheng, X., Wu, Z., Wu, D., Ding, X., Ju, C., Zhou, Z., Wan, L., Zhao, W., et al. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12506 · Cited by 3
Zhao, J., Jin, J., Li, Y., Zhang, S., Li, F., Cui, J., Wang, Z., Yan, D., & Qiu, F. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119318 · Cited by 3
Zhang, R., Li, X., Liang, X., Kuang, Y., Chen, X., Niu, Y., Ye, L., Li, D., Zhou, X., & Sun, C. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101433 · Cited by 2
Lee, C.-W. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113844 · Cited by 2
Kamada, Y., Sumida, Y., Takahashi, H., Ishiba, H., Kawanaka, M., Tada, T., Yoneda, M., Imajo, K., Seko, Y., Fujii, H., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i2.114097 · Cited by 2
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
Sahu, P., & Satapathy, T. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11050-6 · Cited by 3
Non-invasive tests for evaluating treatment response in NAFLD
Bantel, H., & Schulze‐Osthoff, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.015 · Cited by 2
Chen, D., Zhang, Y., Zhou, Y., & Liu, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.016 · Cited by 1
The evolving role of non-invasive assessment for liver fibrosis
Wang, P., Pan, C. Q., Liu, Y., & Zhang, J. (2023) · Gastroenterology report · doi:10.1093/gastro/goae080 · Cited by 1
Niriella, M. A., Dassanayake, U. B., Madurapperuma, C. P., Wijesingha, I. P., Silva, A. P. D., & de Silva, H. J. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2586690 · Cited by 1
Sanyal, A. J., Ratziu, V., Hajji, Y., Magnanensi, J., Deledicque, S., Majd, Z., Hum, D. W., Staels, B., Connelly, M. A., Francque, S., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000844 · Cited by 1
Sanyal, A. J., Abdelmalek, M. F., & Loomba, R. S. (2026) · Hepatology · doi:10.1097/hep.0000000000001734 · Cited by 1
Sharma, H., Tyagi, S., Verma, S., Ghosh, S., & Pande, M. S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113291 · Cited by 1
Jensen, E. L., Thiele, M. S., Torp, N., Johansen, S., Hansen, J. K., Sørensen, M. D., Hansen, C. D., Hovland, M., Andersen, M. L., Semmler, G., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.027 · Cited by 1
The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications
Zheng, W., Feng, Q., Wang, J., Li, X. X., & Yin, S. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1811118 · Cited by 1
Liu, J., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879097 · Cited by 1
Chemoprevention in hepatocellular carcinoma
Suzuki, H., Ng, C. H., Tan, D. J. H., Teng, M. L. P., Kawaguchi, T., & Huang, D. Q. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00614-7 · Cited by 1
Praxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1
Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
Fernández‐Iglesias, A., & Gracia‐Sancho, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00023-1 · Cited by 1
Perspectives of Drug Therapy for Non-Alcoholic Steatohepatitis-Related Liver Fibrosis
Garbuzenko, D. V. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10002 · Cited by 1
Excess Iron added to the diet induces the apoptosis of chicken’s liver through the PI3KAKT mTOR axisPreprint
Sun, F., An, Y., Lv, X.-L., Sun, N., Lv, X., Liu, C., & Gao, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2212549/v1 · Cited by 1
Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences
Younossi, Z. M., & Henry, L. L. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/22-00150 · Cited by 1
Yao, D.-W., Jiang, H.-X., & Qin, S. (2024) · Hepatitis Monthly · doi:10.5812/hepatmon-138304
Noninvasive evaluation of liver fibrosis in MASLD—Imaging/elastography based
Zhang, X., Li, G., Lin, H., Wong, V. W., & Wong, G. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00005-4
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 2
Histopathology of MASLD: Insights into Liver Tissue Changes
Francque, S., & Driessen, A. L. C. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_6
Nichtinvasive Marker zur Bestimmung der Fibrose und Zirrhose
Jhaisha, S. A., & Trautwein, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_6
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Pharmacological strategies targeting hepatocyte-mediated crosstalk in liver fibrosis
Zhang, Y., Wei, M., Zhou, X.-Y., Qi, L., & Liu, Q. Q. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.01.010 · Cited by 1
Zhang, Z., Zheng, X., Dong, C., Li, P., Lin, Y., Sun, Z., Li, W., Liu, X., Li, J. J., Li, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03220
Cao, D., Wang, J., Hou, C., Zeng, J., Tian, B., Liu, Y., Luo, X. H., Tian, J., Zhou, M., Li, P., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1736295
Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review
Cao, G., Zhao, H., Lin, G., Chen, J., Gao, C., Méndez‐Sánchez, N., Gao, F., & Qi, X. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03696-z
Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome
Liu, J.-C., Zeng, Q., Li, D., Ma, T., Yeung, W. S. B., Zhang, T., & Duan, Y. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02180-x
Loomba, R. S., Chen, R., Wang, Y., Bettencourt, R., Madamba, E. V., Tesfai, K., Richards, L., Muthiah, M. D., Tan, E., Young, D. Y., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001856 · Cited by 1
Passos, P. R. C., Filho, V. O. C., Moraes, B. D. F., Silveira, I. B., SÜFFERT, L. C., & Cançado, G. G. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.030
Liu, J., Sun, K., Liu, H., Zhu, M., Li, C., He, Y., & Qin, L. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70318
Shen, Y., Cai, X., 郑怀军, Zheng, Z., Wu, L., Yuan, M., Jin, X., Ye, D., & Feng, Y. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103036
Metadata
- Authors
- Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., Natha, M., Shringarpure, R., Granston, T., Venugopal, A., & Ratziu, V.
- Affiliations
- Northwestern University (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Inova Health System (US)
- Pinnacle Clinical Research (US)
- University of California San Diego (US)
- Virginia Commonwealth University (US)
- Intercept Pharmaceuticals (United States) (US)
- Inserm (FR)
- Corresponding author
- Ratziu, Vlad
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 76
- Issue
- 3
- Pages
- 536-548
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3208671080
- Cited by
- 164
- References
- 45
- Citations by year
- 2026: 20 · 2025: 35 · 2024: 46 · 2023: 43 · 2022: 20
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Open Access CRIS of the University of Bern
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, obeticholic acid, liver fibrosis, non-invasive tests, treatment response, vibration-controlled transient elastography, FIB-4, FibroTest, FibroMeter, liver stiffness, alanine aminotransferase, histological response, fibrosis regression, liver cirrhosis
- MeSH terms
- Adult, Aged, Chenodeoxycholic Acid, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Liver Function Tests, Male, Middle Aged, Placebos, Logistic Models, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
